Stand out for this role — generate a tailored resume and cover letter in about a minute.
Celcuity Inc. is seeking an Associate Director / Director, Patient Marketing to drive the launch of REVTORPYK, a novel PI3K/AKT/mTOR inhibitor for advanced breast cancer.
You will lead patient marketing strategy, develop the promotional platform, and collaborate with APPs, nurses, caregivers, and advocacy groups. The role emphasizes omni-channel tactics, educational content, and regulatory compliance, with strong cross-functional partnership across commercial operations, sales, medical, and
The Associate Director / Director, Patient Marketing will play a pivotal role in the launch of Celcuity’s first product – REVTORPYK. REVTORPYK is a novel, multi-target PI3K/AKT/mTOR (PAM) pathway inhibitor initially focused on advanced breast cancer, with the potential for additional indications. The successful candidate will develop a comprehensive, patient-centered promotional engagement strategy, lead the development of the patient marketing promotional platform, and create related tactics for patients, caregivers, advanced practice providers (APPs), and other nursing stakeholders. Additionally, this person will help represent the voice of the patient and caregiver in the development of brand strategy and commercial priorities. This is a highly visible, high-growth role that requires strong strategic thinking, superior cross-functional collaboration, and the ability to operate at all levels of a rapidly growing organization.
Celcuity is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA‑approved product is REVTORPYK (gedatolisib), a potent, pan‑PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.
The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first‑line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.
Celcuity is an Equal‑Opportunity Employer.
Celcuity is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.
The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. Celcuity also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.